| Display title | Chemistry:Otelixizumab |
| Default sort key | Otelixizumab |
| Page length (in bytes) | 7,615 |
| Namespace ID | 3022 |
| Namespace | Chemistry |
| Page ID | 766877 |
| Page content language | en - English |
| Page content model | wikitext |
| Indexing by robots | Allowed |
| Number of redirects to this page | 0 |
| Counted as a content page | Yes |
| HandWiki item ID | None |
| Edit | Allow all users (infinite) |
| Move | Allow all users (infinite) |
| Page creator | imported>Corlink |
| Date of page creation | 20:34, 5 February 2024 |
| Latest editor | imported>Corlink |
| Date of latest edit | 20:34, 5 February 2024 |
| Total number of edits | 1 |
| Recent number of edits (within past 90 days) | 0 |
| Recent number of distinct authors | 0 |
Description | Content |
Article description: (description)
This attribute controls the content of the description and og:description elements. | Otelixizumab, also known as TRX4, is a monoclonal antibody, which is being developed for the treatment of type 1 diabetes and other autoimmune diseases. The antibody is being developed by Tolerx, Inc. in collaboration with GlaxoSmithKline and is being manufactured by Abbott Laboratories. |
